Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Total Current Liabilities (2022 - 2025)

Zentalis Pharmaceuticals has reported Total Current Liabilities over the past 4 years, most recently at $36.6 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $36.6 million for Q4 2025, down 30.66% from a year ago — trailing twelve months through Dec 2025 was $36.6 million (down 30.66% YoY), and the annual figure for FY2025 was $36.6 million, down 30.66%.
  • Total Current Liabilities for Q4 2025 was $36.6 million at Zentalis Pharmaceuticals, down from $37.2 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for ZNTL hit a ceiling of $69.4 million in Q4 2023 and a floor of $36.6 million in Q4 2025.
  • Median Total Current Liabilities over the past 4 years was $53.4 million (2022), compared with a mean of $51.9 million.
  • Biggest five-year swings in Total Current Liabilities: grew 29.6% in 2023 and later plummeted 41.49% in 2025.
  • Zentalis Pharmaceuticals' Total Current Liabilities stood at $56.6 million in 2022, then increased by 22.45% to $69.4 million in 2023, then dropped by 23.99% to $52.7 million in 2024, then crashed by 30.66% to $36.6 million in 2025.
  • The last three reported values for Total Current Liabilities were $36.6 million (Q4 2025), $37.2 million (Q3 2025), and $39.0 million (Q2 2025) per Business Quant data.